Stock 27F0 KALA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials KALA BIO, Inc. Deutsche Boerse AG

Equities

27F0

US4831192020

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 11:50:48 01/07/2024 BST 		5-day change 1st Jan Change
6.705 EUR +8.32% Intraday chart for KALA BIO, Inc. +30.50% -2.04%
06-28 KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP CI
06-27 Top Midday Gainers MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 127.5 380.2 79.26 60.86 18.85 19.97 -
Enterprise Value (EV) 1 113.2 298.9 66.05 -9.624 18.85 19.97 19.97
P/E ratio -1.34 x -3.41 x -0.55 x -1.29 x -0.4 x -0.49 x -0.94 x
Yield - - - - - - -
Capitalization / Revenue 21 x 59.8 x 7.05 x 15.6 x - - -
EV / Revenue 21 x 59.8 x 7.05 x 15.6 x - - -
EV / EBITDA -1,647,066 x -4,636,065 x - - - - -
EV / FCF -1,355,233 x -4,104,126 x -726,306 x - - - -
FCF Yield -0% -0% -0% - - - -
Price to Book 4.48 x 3.55 x 4.72 x - - - -
Nbr of stocks (in thousands) 691 1,122 1,310 1,595 2,693 2,816 -
Reference price 2 184.5 339.0 60.50 38.15 7.000 7.090 7.090
Announcement Date 12/02/20 25/02/21 29/03/22 03/03/23 29/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 6.074 6.362 11.24 3.892 - - -
EBITDA -77.39 -82.01 - - - - -
EBIT 1 -88.22 -96.23 -130.2 -81.71 -39.66 -49.18 -52.4
Operating Margin -1,452.49% -1,512.59% -1,158.76% -2,099.33% - - -
Earnings before Tax (EBT) 1 -94.35 -104.3 -142.6 -44.82 -42.2 -50.65 -52.54
Net income 1 -94.35 -104.3 -142.6 -44.82 -42.2 -50.65 -52.54
Net margin -1,553.29% -1,639.85% -1,268.73% -1,151.64% - - -
EPS 2 -138.0 -99.50 -109.5 -29.48 -17.35 -14.49 -7.570
Free Cash Flow -94.06 -92.64 -109.1 - - - -
FCF margin -1,548.49% -1,456.08% -970.83% - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 12/02/20 25/02/21 29/03/22 03/03/23 29/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1.856 1.372 2.1 0.42 - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -46.82 -30.91 -25.97 -14.57 -10.25 -11.68 -9.599 -8.762 -9.619 -11.93 -12 -12.5 -12.75 - -
Operating Margin -2,522.36% -2,253.21% -1,236.76% -3,468.81% - - - - - - - - - - -
Earnings before Tax (EBT) 1 -47.57 -32.94 -28.11 29.07 -12.84 -14.46 -10.41 -8.704 -8.627 -11.81 -12.5 -13.03 -13.3 - -
Net income 1 -47.57 -32.94 -28.11 29.07 -12.84 -14.46 -10.41 -8.704 -8.627 -11.81 -12.5 -13.03 -13.3 - -
Net margin -2,562.93% -2,400.95% -1,338.62% 6,922.14% - - - - - - - - - - -
EPS 2 -34.00 -22.50 -19.00 19.25 -7.970 -6.990 -4.360 -3.410 -2.990 -4.200 -4.405 -4.530 -2.550 -2.620 -2.000
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 29/03/22 16/05/22 11/08/22 08/11/22 03/03/23 09/05/23 04/08/23 13/11/23 29/03/24 14/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 14.3 81.3 13.2 70.5 - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -94.1 -92.6 -109 - - - -
ROE (net income / shareholders' equity) -140% -161% - - - - -
ROA (Net income/ Total Assets) -50.3% -55.5% -54.9% - - - -
Assets 1 187.6 188 259.8 - - - -
Book Value Per Share 41.10 95.50 12.80 - - - -
Cash Flow per Share -136.0 -86.60 - - - - -
Capex 1.34 1.94 0.89 - - - -
Capex / Sales 21.98% 30.52% 7.88% - - - -
Announcement Date 12/02/20 25/02/21 29/03/22 03/03/23 29/03/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.09 USD
Average target price
18.33 USD
Spread / Average Target
+158.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.30% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.17% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.17% 224B
NOVARTIS AG Stock Novartis AG
+13.39% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. KALA Stock
  4. 27F0 Stock
  5. Financials KALA BIO, Inc.